Table 2.
Morphological subtypes of classic variants of primary central high-grade osteosarcomas treated with neo-adjuvant chemotherapy: correlation with response to neo-adjuvant chemotherapy and presence of FGFR1 amplification.
| Osteosarcoma subtype | Osteoblastic 105 (57.1%) | Chondroblastic 40 (21.7%) | Fibroblastic 21 (11.4%) | Telangiectatic 14 (7.6%) | Others 4 (2.2%) | Total 184 (100%) |
|---|---|---|---|---|---|---|
| Number of “Good responders” (%) | 45 | 19 | 5 | 6 | 0 | 75 (40.8) |
| Number of ‘Poor responders’ (%) | 60 | 21 | 16 | 8 | 4 | 109 (59.2) |
| Number of cases with amplification (% of subtype)1 | 7 (6.7) | 3 (7.5) | 7 (33.3) | 2 (14.3) | 0 | 19 |
1
All cases with FGFR1 amplification showed a poor response to neo-adjuvant chemotherapy.